Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase

Cheol Yong Yoon, Young Jun Shim, Eun Ho Kim, Ju-Han Lee, Nam Hee Won, Jeong Hun Kim, In Sun Park, Duck Ki Yoon, Bon Hong Min

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Recently, pegylated arginine deiminase (ADI; EC 3.5.3.6) has been used to treat the patients with hepatocellular carcinoma or melanoma, in which the level of argininosuccinate synthetase (ASS) activity is low or undetectable. The efficacy of its antitumor activity largely depends on the level of intracellular ASS, which enables tumor cells to recycle citrulline to arginine. Thus, we examined the expression levels of ASS in various cancer cells and found that it is low in renal cell carcinoma (RCC) cells, rendering the cells highly sensitive to arginine deprivation by ADI treatment. Immunohistochemical analysis revealed that in biopsy specimens from RCC patients (n = 98), the expression of ASS is highly demonstrated in the epithelium of normal proximal tubule but not seen in tumor cells. Furthermore, RCC cells treated with ADI showed remarkable growth retardation in a dose dependent manner. ADI also exerted in vivo antiproliferative effect on the allografted renal cell carcinoma (RENCA) tumor cells and prolonged the survival of tumor-bearing mice. Histological examination of the tumors revealed that tumor angiogenesis and vascular endothelial growth factor (VEGF) expression were significantly diminished by ADI administration. Therefore, these findings suggest that arginine deprivation by ADI could provide a beneficial strategy for the treatment of RCC in ways of inhibitions of arginine availability and neovascularization.

Original languageEnglish
Pages (from-to)897-905
Number of pages9
JournalInternational Journal of Cancer
Volume120
Issue number4
DOIs
Publication statusPublished - 2007 Feb 15

Fingerprint

Argininosuccinate Synthase
Renal Cell Carcinoma
Arginine
Neoplasms
Citrulline
arginine deiminase
Vascular Endothelial Growth Factor A
Hepatocellular Carcinoma
Melanoma
Cell Survival
Epithelium
Biopsy

Keywords

  • Arginine deiminase
  • Argininosuccinate synthetase
  • Renal cell carcinoma
  • Tumor angiogenesis
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. / Yoon, Cheol Yong; Shim, Young Jun; Kim, Eun Ho; Lee, Ju-Han; Won, Nam Hee; Kim, Jeong Hun; Park, In Sun; Yoon, Duck Ki; Min, Bon Hong.

In: International Journal of Cancer, Vol. 120, No. 4, 15.02.2007, p. 897-905.

Research output: Contribution to journalArticle

Yoon, Cheol Yong ; Shim, Young Jun ; Kim, Eun Ho ; Lee, Ju-Han ; Won, Nam Hee ; Kim, Jeong Hun ; Park, In Sun ; Yoon, Duck Ki ; Min, Bon Hong. / Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. In: International Journal of Cancer. 2007 ; Vol. 120, No. 4. pp. 897-905.
@article{47e4e55b799e4189a88b1a50f829f1c6,
title = "Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase",
abstract = "Recently, pegylated arginine deiminase (ADI; EC 3.5.3.6) has been used to treat the patients with hepatocellular carcinoma or melanoma, in which the level of argininosuccinate synthetase (ASS) activity is low or undetectable. The efficacy of its antitumor activity largely depends on the level of intracellular ASS, which enables tumor cells to recycle citrulline to arginine. Thus, we examined the expression levels of ASS in various cancer cells and found that it is low in renal cell carcinoma (RCC) cells, rendering the cells highly sensitive to arginine deprivation by ADI treatment. Immunohistochemical analysis revealed that in biopsy specimens from RCC patients (n = 98), the expression of ASS is highly demonstrated in the epithelium of normal proximal tubule but not seen in tumor cells. Furthermore, RCC cells treated with ADI showed remarkable growth retardation in a dose dependent manner. ADI also exerted in vivo antiproliferative effect on the allografted renal cell carcinoma (RENCA) tumor cells and prolonged the survival of tumor-bearing mice. Histological examination of the tumors revealed that tumor angiogenesis and vascular endothelial growth factor (VEGF) expression were significantly diminished by ADI administration. Therefore, these findings suggest that arginine deprivation by ADI could provide a beneficial strategy for the treatment of RCC in ways of inhibitions of arginine availability and neovascularization.",
keywords = "Arginine deiminase, Argininosuccinate synthetase, Renal cell carcinoma, Tumor angiogenesis, Vascular endothelial growth factor",
author = "Yoon, {Cheol Yong} and Shim, {Young Jun} and Kim, {Eun Ho} and Ju-Han Lee and Won, {Nam Hee} and Kim, {Jeong Hun} and Park, {In Sun} and Yoon, {Duck Ki} and Min, {Bon Hong}",
year = "2007",
month = "2",
day = "15",
doi = "10.1002/ijc.22322",
language = "English",
volume = "120",
pages = "897--905",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase

AU - Yoon, Cheol Yong

AU - Shim, Young Jun

AU - Kim, Eun Ho

AU - Lee, Ju-Han

AU - Won, Nam Hee

AU - Kim, Jeong Hun

AU - Park, In Sun

AU - Yoon, Duck Ki

AU - Min, Bon Hong

PY - 2007/2/15

Y1 - 2007/2/15

N2 - Recently, pegylated arginine deiminase (ADI; EC 3.5.3.6) has been used to treat the patients with hepatocellular carcinoma or melanoma, in which the level of argininosuccinate synthetase (ASS) activity is low or undetectable. The efficacy of its antitumor activity largely depends on the level of intracellular ASS, which enables tumor cells to recycle citrulline to arginine. Thus, we examined the expression levels of ASS in various cancer cells and found that it is low in renal cell carcinoma (RCC) cells, rendering the cells highly sensitive to arginine deprivation by ADI treatment. Immunohistochemical analysis revealed that in biopsy specimens from RCC patients (n = 98), the expression of ASS is highly demonstrated in the epithelium of normal proximal tubule but not seen in tumor cells. Furthermore, RCC cells treated with ADI showed remarkable growth retardation in a dose dependent manner. ADI also exerted in vivo antiproliferative effect on the allografted renal cell carcinoma (RENCA) tumor cells and prolonged the survival of tumor-bearing mice. Histological examination of the tumors revealed that tumor angiogenesis and vascular endothelial growth factor (VEGF) expression were significantly diminished by ADI administration. Therefore, these findings suggest that arginine deprivation by ADI could provide a beneficial strategy for the treatment of RCC in ways of inhibitions of arginine availability and neovascularization.

AB - Recently, pegylated arginine deiminase (ADI; EC 3.5.3.6) has been used to treat the patients with hepatocellular carcinoma or melanoma, in which the level of argininosuccinate synthetase (ASS) activity is low or undetectable. The efficacy of its antitumor activity largely depends on the level of intracellular ASS, which enables tumor cells to recycle citrulline to arginine. Thus, we examined the expression levels of ASS in various cancer cells and found that it is low in renal cell carcinoma (RCC) cells, rendering the cells highly sensitive to arginine deprivation by ADI treatment. Immunohistochemical analysis revealed that in biopsy specimens from RCC patients (n = 98), the expression of ASS is highly demonstrated in the epithelium of normal proximal tubule but not seen in tumor cells. Furthermore, RCC cells treated with ADI showed remarkable growth retardation in a dose dependent manner. ADI also exerted in vivo antiproliferative effect on the allografted renal cell carcinoma (RENCA) tumor cells and prolonged the survival of tumor-bearing mice. Histological examination of the tumors revealed that tumor angiogenesis and vascular endothelial growth factor (VEGF) expression were significantly diminished by ADI administration. Therefore, these findings suggest that arginine deprivation by ADI could provide a beneficial strategy for the treatment of RCC in ways of inhibitions of arginine availability and neovascularization.

KW - Arginine deiminase

KW - Argininosuccinate synthetase

KW - Renal cell carcinoma

KW - Tumor angiogenesis

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33846625891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846625891&partnerID=8YFLogxK

U2 - 10.1002/ijc.22322

DO - 10.1002/ijc.22322

M3 - Article

VL - 120

SP - 897

EP - 905

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -